Filing Flows

Filing Flows › Companies › Tvardi Therapeutics › Cash flow

Tvardi Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$9.2M in Q2 2026 · −$25.0M over twelve months

Operating cash flow−$9.2M
Free cash flow−$9.2M

Analysis

In Q2 2026, Tvardi Therapeutics generated −$9.2M of operating cash flow. That is $3.4M less than in Q2 2025 (−$5.9M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$25.0M; the largest uses were operating cash flow ($25.0M); besides operations, cash came from other investing ($20.5M); the cash balance fell by $4.9M.

Operating cash flow was −$9.2M against net income of −$6.5M. The largest differences: payables −$2.1M, prepaid and other assets −$958K, stock-based pay +$335K.

Free cash flow

Tvardi Therapeutics: free cash flow by quarterTvardi Therapeutics: free cash flow by quarter−$6.7MQ3 2024−$4.8MQ4 2024−$7.7MQ1 2025−$5.9MQ2 2025−$4.3MQ3 2025−$5.7MQ4 2025−$5.9MQ1 2026−$9.2MQ2 2026
Operating cash flow less capital spending.
Tvardi Therapeutics: operating cash flow against capital spendingTvardi Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$6.7M$0Q3 2024−$4.8M$0Q4 2024−$7.7M$0Q1 2025−$5.9M$0Q2 2025−$4.3M$0Q3 2025−$5.7M$0Q4 2025−$5.9M$0Q1 2026−$9.2M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$9.2M, Capital spending $0.

Capital allocation, year by year

Tvardi Therapeutics: where the cash came from (up) and went (down), by fiscal yearTvardi Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$60.1MFY2021: Shares issued $1.6MFY2021: Asset sales $70KFY2021: Capital spending −$39K$1.7MFY2021FY2022: Operating cash flow −$78.7MFY2022: Shares issued $311KFY2022: Capital spending −$43K$311KFY2022FY2023: Operating cash flow −$92.1MFY2023: Shares issued $1.7MFY2023: Capital spending −$2.4M$1.7MFY2023FY2024: Operating cash flow −$18.3MFY2024: Net borrowing $28.3MFY2024: Shares issued $5KFY2024: Capital spending −$1.0M$28.3MFY2024FY2025: Operating cash flow −$23.5MFY2025: Shares issued $532K$532KFY2025
Over these 5 years operating cash flow totalled −$273M; the largest uses were operating cash flow ($273M) and capital spending ($3.5M). Cash-flow statements as filed.

Where the cash came from and went

Tvardi Therapeutics: sources (+) and uses (−) of cash, Q2 2026Tvardi Therapeutics: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$9.2MOther investing$5.1MCash drawn (+) / kept (−)$4.1M
Tvardi Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Tvardi Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$25.0MOther investing$20.5MCash drawn (+) / kept (−)$4.9MNot reconciled−$321K

From profit to cash

Tvardi Therapeutics: net income to operating cash flow, Q2 2026Tvardi Therapeutics: net income to operating cash flow, Q2 2026Net income−$6.5MDepreciation & amortization$23KStock-based pay$335KPayables−$2.1MPrepaid and other assets−$958KOperating cash flow−$9.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$9.2M—$4.1M−$9.2M
Q1 2026−$5.9M—$883K−$5.9M
Q4 2025−$5.7M$1K$684K−$5.7M
Q3 2025−$4.3M$107K−$770K−$4.3M
Q2 2025−$5.9M$421K−$9.2M−$5.9M
Q1 2025−$7.7M$3K$20.2M−$7.7M
Q4 2024−$4.8M—−$22.2M−$4.8M
Q3 2024−$6.7M—$6.7M−$6.7M

Tvardi Therapeutics: income statement and cash flow

Tvardi Therapeutics, Q1 2025: revenue $2.6M (+20% year over year), operating margin -92.9%. The chart follows the revenue to costs, profit and cash.

Tvardi Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.